Posted by Michael Wonder on 27 May 2017
Drug approvals bounce back as R&D labs churn out new winners
25 May 2017 - The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.
The U.S. FDA has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016, and just nine at this stage last year.
The EMA has recommended 42 compared with a 2016 total of 81, and 31 in the first five months of last year. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.
